z-logo
open-access-imgOpen Access
Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
Author(s) -
AlonsoGordoa Teresa
Publication year - 2022
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4901
Subject(s) - medicine , refractory (planetary science) , thyroid cancer , central nervous system , thyroid , cancer , oncology , clinical trial , radiation therapy , physics , astrobiology
The diagnosis of central nervous system metastases in patients with radioiodine refractory differentiated thyroid cancer is a late and rare event that occurs in less than 1% of patients. Definitive conclusions on the overall clinical management cannot be drawn due to the limited number of patients included in retrospective series or post hoc analysis from clinical trials. However, most data show a trend to an increased benefit from a multimodal approach. Local treatment based on surgical and/or radiation techniques is highly encouraged for symptom control and to reduce tumor burden in this location despite a high risk of clinical complications. In addition, systemic treatment with novel tyrosine kinase inhibitors has demonstrated activity in this subgroup of patients, improving an otherwise unfavorable prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here